NEWSROOM Press Releases

    254 Results

    Biodesix® Named Innovative Company of the Year at 2016 IQ Awards

    Biodesix won the BizIQ award, 2016 Innovative Company of the Year.

    Biodesix’ VeriStrat Test Now Covered By Humana, Medical Mutual of Ohio, PreferredOne

    Humana, Medical Mutual of Ohio and Preferred One independently determined and published a policy stating that VeriStrat can be considered medically necessary for patients with (NSCLC)

    More Information on Disease State and Trial Options for Patients with Advanced Non-Small Cell Lung Cancer; Evaluating Automated and Manual Workflows in cfDNA Extraction

    Biodesix, in partnership with BioRad and Qiagen, presents data from new studies at AMP.

    VeriStrat® Test Identifies Patients with Squamous Cell Carcinoma of the Lung Who Are More Likely to Have Improved Survival on Afatinib Therapy

    VeriStrat® Test identifies patients with squamous cell carcinoma of the lung who are more likely to have improved survival on Afatinib therapy.

    Independent Study Data Supporting Clinical Use of Biodesix®’ Blood-Based Tests To Be Presented At CHEST Conference

    Independent Study Data supports clinical use of Biodesix’s blood-based tests at CHEST conference.

    Biodesix®’ VeriStrat® Test Identifies T790M-Mutated Advanced Non-Small Cell Lung Cancer Patients Who Are More Likely to Have Improved Progression-Free Survival on Third Generation EGFR-TKI Therapy

    Biodesix's VeriStrat test identifies T790M-mutated advanced non-small cell lung cancer patients who are more likely to have improved progression-free survival on third generation EGFR-TKI therapy

    Biodesix Presenting Results From Three Studies at SITC Annual Meeting; Oral Poster Presentation, Two Additional Poster Presentations

    Biodesix will present data from three studies at SITC's annual meeting.

    Multi-Institutional Data Supporting Clinical Use of Biodesix’ Blood-Based Tests Presented Today at IASLC Conference

    Multi-institutional data supporting clinical use of Biodesix blood tests was presented at the IASCL Chicago thoracic conference

    Biodesix’s Diagnostic Cortex™ Platform Used in Three Studies Presented at SITC

    The study results indicate that the tests have the potential to offer clinically relevant information that could help physicians selecting immunotherapies for their patients make the best decision

    Independent Data Demonstrates Clinical Utility of Biodesix®’ Blood-Based Tests

    Data from an independent study demonstrated the clinical utiity of Biodesix' VeriStrat and GeneStrat tests.

    1 2 3 4 5 6 7 8 9